153 related articles for article (PubMed ID: 11374314)
1. Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy.
Kollmannsberger C; Mayer F; Kuczyk M; Kanz L; Bokemeyer C
World J Urol; 2001 Apr; 19(2):120-5. PubMed ID: 11374314
[TBL] [Abstract][Full Text] [Related]
2. Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG).
Bokemeyer C; Kollmannsberger C; Harstrick A; Beyer J; Gerl A; Casper J; Metzner B; Hartmann JT; Schmoll HJ; Kanz L
Int J Cancer; 1999 Dec; 83(6):848-51. PubMed ID: 10597209
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in management of patients with platinum-refractory testicular germ cell tumors.
Kollmannsberger C; Nichols C; Bokemeyer C
Cancer; 2006 Mar; 106(6):1217-26. PubMed ID: 16463389
[TBL] [Abstract][Full Text] [Related]
4. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
Bokemeyer C
Oncology; 1998; 55(3):177-88. PubMed ID: 9560052
[TBL] [Abstract][Full Text] [Related]
5. Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
Soulié P; Garrino C; Bensmaïne MA; Bekradda M; Brain E; Di Palma M; Goupil A; Misset JL; Cvitkovic E
J Cancer Res Clin Oncol; 1999 Dec; 125(12):707-11. PubMed ID: 10592105
[TBL] [Abstract][Full Text] [Related]
6. The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors.
Bokemeyer C; Hartmann JT; Kuczyk MA; Truss MC; Beyer J; Jonas U; Kanz L
World J Urol; 1996; 14(6):354-9. PubMed ID: 8986035
[TBL] [Abstract][Full Text] [Related]
7. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
Kollmannsberger C; Rick O; Derigs HG; Schleucher N; Schöffski P; Beyer J; Schoch R; Sayer HG; Gerl A; Kuczyk M; Spott C; Kanz L; Bokemeyer C
J Clin Oncol; 2002 Apr; 20(8):2031-7. PubMed ID: 11956262
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.
Bokemeyer C; Gerl A; Schöffski P; Harstrick A; Niederle N; Beyer J; Casper J; Schmoll HJ; Kanz L
J Clin Oncol; 1999 Feb; 17(2):512-6. PubMed ID: 10080593
[TBL] [Abstract][Full Text] [Related]
9. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel in salvage therapy for germ cell tumors.
Motzer RJ
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-83-S15-85. PubMed ID: 9346229
[TBL] [Abstract][Full Text] [Related]
11. Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer.
Hartmann JT; Kuczyk MA; Kollmannsberger C; Kanz L; Bokemeyer C
World J Urol; 1999 Oct; 17(5):324-33. PubMed ID: 10552153
[TBL] [Abstract][Full Text] [Related]
12. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer.
Bokemeyer C; Beyer J; Metzner B; Ruther U; Harstrick A; Weissbach L; Kohrmann U; Verbeek W; Schmoll HJ
Ann Oncol; 1996 Jan; 7(1):31-4. PubMed ID: 9081388
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer.
Kollmannsberger C; Gerl A; Schleucher N; Beyer J; Kuczyk M; Rick O; Casper J; Sosada M; Rie C; Kanz L; Bokemeyer C
Anticancer Drugs; 2000 Aug; 11(7):535-9. PubMed ID: 11036955
[TBL] [Abstract][Full Text] [Related]
15. Recent strategies for the use of paclitaxel in the treatment of urological malignancies.
Bokemeyer C; Hartmann JT; Kuczyk MA; Truss MC; Kollmannsberger C; Beyer J; Jonas U; Kanz L
World J Urol; 1998; 16(2):155-62. PubMed ID: 12073232
[TBL] [Abstract][Full Text] [Related]
16. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
Kondagunta GV; Bacik J; Donadio A; Bajorin D; Marion S; Sheinfeld J; Bosl GJ; Motzer RJ
J Clin Oncol; 2005 Sep; 23(27):6549-55. PubMed ID: 16170162
[TBL] [Abstract][Full Text] [Related]
17. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.
Lotz JP; André T; Donsimoni R; Firmin C; Bouleuc C; Bonnak H; Merad Z; Esteso A; Gerota J; Izrael V
Cancer; 1995 Feb; 75(3):874-85. PubMed ID: 7828139
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.
Motzer RJ; Sheinfeld J; Mazumdar M; Bains M; Mariani T; Bacik J; Bajorin D; Bosl GJ
J Clin Oncol; 2000 Jun; 18(12):2413-8. PubMed ID: 10856101
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy in patients with metastatic or relapsed germ-cell tumours.
Rick O; Siegert W; Beyer J
Cancer Treat Rev; 2001 Oct; 27(5):283-8. PubMed ID: 11871864
[TBL] [Abstract][Full Text] [Related]
20. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.
Fenner M; Oing C; Dieing A; Gauler T; Oechsle K; Lorch A; Hentrich M; Kopp HG; Bokemeyer C; Honecker F
J Cancer Res Clin Oncol; 2019 Mar; 145(3):717-723. PubMed ID: 30232558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]